Ascendis Pharma A/s income statement

In fiscal 2025, Ascendis Pharma A/s reported revenue of $814m, up 106.9% on the year before, operating income of −$154m (a -18.9% margin) and net income of −$258m, or −$4.25 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Ascendis Pharma A/s: income statement, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	9	5	2	13	15	8	9	54	288	393	814
Cost of revenue	—	—	—	—	0	0	4	13	48	48	107
Gross profit	—	—	—	—	15	8	5	41	240	346	707
Research and development	45	73	113	166	215	298	350	400	447	332	343
Operating income	−46	−81	−126	−183	−254	−377	−534	−592	−493	−302	−154
Interest expense	0	0	0	0	1	2	5	32	48	71	91
Income before tax	−37	−76	−141	−154	−244	−478	−454	−609	−513	−404	−240
Income tax	−1	−0	−1	−0	−0	−0	−0	6	8	5	17
Net income	−37	−76	−140	−154	−244	−478	−454	−614	−521	−409	−258
Diluted EPS	−$1.54	−$2.86	−$4.16	—	—	—	−$8.28	−$10.96	−$9.25	−$7.07	−$4.25
Diluted shares (average)	24m	27m	34m	41m	47m	51m	55m	56m	56m	58m	61m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ASND vs TLX ASND vs TGTX ASND vs IONS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ascendis Pharma A/s's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ascendis Pharma A/s.